The amount of reduction in milestone payments due upon performing specified services.

No definition available.

Name:	clym_MilestonePaymentAmountReduced
Namespace Prefix:	clym_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount due from the Company upon achievement of specified milestones, as part of a license agreement.

+ References

No definition available.

+ Details

Name:	clym_MilestonePayments
Namespace Prefix:	clym_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount due as a result of achievement of specified milestones, as of the balance sheet date.

+ References

No definition available.

+ Details

Name:	clym_MilestonePaymentsDue
Namespace Prefix:	clym_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of upfront payment paid during the period as part of a license agreement.

+ References

No definition available.

+ Details

Name:	clym_UpfrontPaymentPaid
Namespace Prefix:	clym_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_OtherCommitmentsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-18

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=clym_AcelyrinAssetPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=clym_MabworksAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FinancialInstrumentAxis=clym_DevelopmentAndRegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FinancialInstrumentAxis=clym_CommercialMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FinancialInstrumentAxis=clym_MilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=clym_CrhAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=clym_ProbiogenAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FinancialInstrumentAxis=clym_ManufacturingServicesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FinancialInstrumentAxis=clym_UpfrontPaymentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FinancialInstrumentAxis=clym_DevelopmentRegulatoryAndCommercialMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FinancialInstrumentAxis=clym_DevelopmentRegulatoryCommercialAndSalesMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FinancialInstrumentAxis=clym_DevelopmentManufacturingAndCommercialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FinancialInstrumentAxis=clym_SalesMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and Contingencies - Additional Information (Details) $ in Thousands, € in Millions, £ in Millions		3 Months Ended	12 Months Ended
	Jan. 08, 2025 USD ($)	Mar. 31, 2025 USD ($)	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)	Jan. 31, 2024 GBP (£)	Jan. 11, 2024 USD ($)	Feb. 28, 2021 EUR (€)
Other Commitments [Line Items]
Research and development expense			$ 46,713	$ 14,336
Acelyrin Asset Purchase Agreement [Member]
Other Commitments [Line Items]
Milestone Payments Due			0
Mabworks Agreement [Member]
Other Commitments [Line Items]
Upfront Payment Paid	$ 9,000
Development and Regulatory Milestones [Member] \| Mabworks Agreement [Member]
Other Commitments [Line Items]
Milestone Payments	30,000
Commercial Milestones [Member] \| Mabworks Agreement [Member]
Other Commitments [Line Items]
Milestone Payments	$ 832,000
Milestone [Member] \| CRH Agreement [Member]
Other Commitments [Line Items]
Research and development expense			1,000
Milestone [Member] \| ProBioGen Agreement [Member]
Other Commitments [Line Items]
Research and development expense			2,700
Milestone [Member] \| Mabworks Agreement [Member]
Other Commitments [Line Items]
Research and development expense			1,000
Manufacturing Services [Member] \| ProBioGen Agreement [Member]
Other Commitments [Line Items]
Milestone Payment, Amount Reduced			1,200				€ 1.1
Upfront Payment [Member] \| Mabworks Agreement [Member]
Other Commitments [Line Items]
Research and development expense		$ 9,000
Maximum [Member] \| Development Regulatory and Commercial Milestones [Member] \| Acelyrin Asset Purchase Agreement [Member]
Other Commitments [Line Items]
Milestone Payments						$ 157,500
Maximum [Member] \| Development Regulatory Commercial and Sales Milestones [Member] \| CRH Agreement [Member]
Other Commitments [Line Items]
Milestone Payments			143,600		£ 106.8
Maximum [Member] \| Development Manufacturing and Commercial [Member] \| ProBioGen Agreement [Member]
Other Commitments [Line Items]
Milestone Payments			11,700				10.0
Maximum [Member] \| Sales Milestones [Member] \| ProBioGen Agreement [Member]
Other Commitments [Line Items]
Milestone Payments			$ 8,200				€ 7.0